The Journal of Clinical Endocrinology & Metabolism · 2015 · 50 citations · 36 references
AgricultureNutritionNutritional SciencesClinical NutritionHuman NutritionNutritional BiochemistryCardiovascular DiseaseCardiovascular NutritionDiabetes MellitusDietary ManagementLipid NutritionMedical Nutrition TherapyCardiac Fatty Acid OxidationCardiac Systolic FunctionCardiometabolic Response To DietDiabetic CardiomyopathyDietary Fat EffectsFatty AcidsLeft Ventricular Systolic Function
CONTEXT: Excessive cardiac long-chain fatty acid (LCFA) metabolism/storage causes cardiomyopathy in animal models of type 2 diabetes. Medium-chain fatty acids (MCFAs) are absorbed and oxidized efficiently. Data in animal models of diabetes suggest MCFAs may benefit the heart. OBJECTIVE: Our objective was to test the effects of an MCFA-rich diet vs an LCFA-rich diet on plasma lipids, cardiac steatosis, and function in patients with type 2 diabetes. DESIGN: This was a double-blind, randomized, 2-week matched-feeding study. SETTING: The study included ambulatory patients in the general community. PATIENTS: Sixteen patients, ages 37-65 years, with type 2 diabetes, an ejection fraction greater than 45%, and no other systemic disease were included. INTERVENTION: Fourteen days of a diet rich in MCFAs or LCFAs, containing 38% as fat in total, was undertaken. MAIN OUTCOME MEASURES: Cardiac steatosis and function were the main outcome measures, with lipidomic changes considered a secondary outcome. RESULTS: The relatively load-independent measure of cardiac contractility, S', improved in the MCFA group (P < .05). Weight-adjusted stroke volume and cardiac output decreased in the LCFA group (both P < .05). The MCFA, but not the LCFA, diet decreased several plasma sphingolipids, ceramide, and acylcarnitines implicated in diabetic cardiomyopathy, and changes in several sphingolipids correlated with improved fasting insulins. CONCLUSIONS: Although a diet high in MCFAs does not change cardiac steatosis, our findings suggest that the MCFA-rich diet alters the plasma lipidome and may benefit or at least not harm cardiac function and fasting insulin levels in humans with type 2 diabetes. Larger, long-term studies are needed to further evaluate these effects in less-controlled settings.
36
Lidia S. Szczepaniak, Pamela Nurenberg, David Léonard et al. · American Journal of Physiology-Endocrinology and Metabolism · 2004 · 1.6K citations
Table of nonprotein respiratory quotient: an update.
François Péronnet, Daniel Massicotte · PubMed · 1991 · 1.2K citations